Response: mechanisms of targeting CD47-SIRPα in hematologic malignancies
Author:
Affiliation:
1. Institute for Stem Cell Biology and Regenerative Medicine, Stanford University, Palo Alto, CA
Publisher
American Society of Hematology
Subject
Cell Biology,Hematology,Immunology,Biochemistry
Link
http://ashpublications.org/blood/article-pdf/119/18/4334/1352930/zh801812004334.pdf
Reference10 articles.
1. Is targeting of CD47-SIRPalpha enough for treating hematopoietic malignancy?;Zhao;Blood,2012
2. Extranodal dissemination of non-Hodgkin lymphoma requires CD47 and is inhibited by anti-CD47 antibody therapy.;Chao;Blood,2011
3. Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma.;Chao;Cell,2010
4. CD47-signal regulatory protein-alpha (SIRPalpha) interactions form a barrier for antibody-mediated tumor cell destruction.;Zhao;Proc Natl Acad Sci U S A,2011
5. CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells.;Majeti;Cell,2009
Cited by 4 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. The CD47-SIRPα signaling axis as an innate immune checkpoint in cancer;Immunological Reviews;2017-03
2. Relationship with immunhistochemical staining extent of CD47 and histopathologic features of bladder tumor;Central European Journal of Urology;2017
3. Reply to “On the Mechanism and Benefit of siRNA-mediated Targeting of CD47 in Cancer”;Molecular Therapy;2013-10
4. Reply to Soto-Pantoja et al. and Zhao et al.: Targeting CD47 on human solid tumors;Proceedings of the National Academy of Sciences;2012-08-24
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3